Sanofi India Board Approves Audited FY25 Results, Final Dividend of ₹48, Appoints Additional Directors
Sanofi India's board approved audited FY25 results and recommended a final dividend of ₹48 per share, in addition to the ₹75 interim dividend. Mrs. Rajani Kesari was appointed as an Additional and Independent Director effective 1st April 2026, while Ms. Sudipta Chakraborty was appointed as an Additional and Whole-time Director from 1st March 2026. Mr. Rodolfo Hrosz resigned as Non-Executive Director, effective 28th February 2026.
The board decisions on dividend and key appointments can influence investor confidence and company strategy.
The announcement includes positive elements such as the approval of financial results and the declaration of a dividend, along with strategic appointments to the board.
Sanofi India Limited's Board of Directors, in a meeting held on 25th February 2026, approved the audited financial results for the quarter and financial year ended 31st December 2025. The board recommended a final dividend of ₹48 per equity share with a face value of ₹10, subject to shareholder approval at the 70th Annual General Meeting (AGM). This is in addition to the interim dividend of ₹75 per equity share declared on 29th October 2025, bringing the total dividend for the year to ₹123 per share.
The Board also approved the appointment of Mrs. Rajani Kesari as an Additional and Independent Director for a 5-year term starting 1st April 2026, and Ms. Sudipta Chakraborty as an Additional and Whole-time Director for a 3-year term starting 1st March 2026. Both appointments are subject to shareholder approval at the upcoming AGM. Ms. Chakraborty will also be a Key Managerial Personnel and a Senior Management Personnel of the Company.
Mr. Rodolfo Hrosz resigned from his position as a Non-Executive Director, effective from the close of business hours on 28th February 2026, citing pre-occupation and commitments. The meeting commenced at 2:00 p.m. and concluded at 5:30 p.m.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under annual results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.